Precision medicine for cervical cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Current cervical cancer treatment selection relies on programmed death ligand 1 (PD-L1) expression for checkpoint inhibitor therapy.
• Emerging data question the accuracy of PD-L1 as a sole predictive biomarker.
• The molecular landscape of cervical cancer is increasingly understood, driving interest in tumor profile-based treatment selection.

Purpose of the Study:

• To review current data on precision medicine for cervical cancer.
• To identify and discuss potential biomarkers for guiding therapy selection.
• To explore ongoing research in cervical cancer therapeutics.

Main Methods:

• Literature review of precision medicine in cervical cancer.
• Analysis of current and emerging biomarkers.
• Discussion of ongoing therapeutic research.

Main Results:

• Programmed death ligand 1 (PD-L1) expression is a current, but potentially limited, biomarker for selecting patients for immunotherapy.
• Tumor profiling, targeting pathways like PI3K and HER2, is gaining importance.
• Further research and clinical trials are needed to validate new biomarkers and targeted therapies.

Conclusions:

• Precision medicine in cervical cancer requires exploring biomarkers beyond PD-L1.
• Targeting specific molecular alterations based on tumor profiles holds promise.
• Patient enrollment in clinical trials is crucial for advancing targeted cervical cancer therapies.